In this regard, GFRAL may act as both an upstream and downstream therapeutic target, with appetite suppression reducing both obesity and correlated visfatin levels, and GDF15 inhibition reducing downstream visfatin mediated pAKT. This evidence concerns the gene GDF15 and obesity disorder.